Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) will likely be announcing its results before the market opens on Wednesday, November 11th. Analysts expect the company to announce earnings of ($9.10) per share for the quarter.
Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) last issued its earnings results on Saturday, August 15th. The company reported ($5.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($21.20) by $16.03. On average, analysts expect Silexion Therapeutics to post ($4.70) EPS for the current fiscal year and ($1.84) EPS for the next fiscal year.
Silexion Therapeutics Trading Up 3.4%
SLXN opened at $0.15 on Wednesday. The firm has a 50-day moving average price of $0.28 and a 200-day moving average price of $6.72. Silexion Therapeutics has a twelve month low of $0.14 and a twelve month high of $32.38.
Wall Street Analysts Forecast Growth
Several research analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Friday, September 11th. Maxim Group cut shares of Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 29th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold”.
Read Our Latest Stock Report on Silexion Therapeutics
About Silexion Therapeutics
Silexion Therapeutics Ltd. (NASDAQ: SLXN) is an Israel-based clinical-stage biotechnology company developing RNA-based medicines for the treatment of solid tumors driven by mutations in the KRAS oncogene. The company’s technology is designed to selectively silence cancer-causing KRAS mutations while limiting exposure to healthy tissue.
Silexion’s lead program, siG12D-LODER, is an investigational RNA interference therapy targeting the KRAS G12D mutation, which is frequently found in pancreatic and other difficult-to-treat cancers.
Further Reading
- Five stocks we like better than Silexion Therapeutics
- Tower Semiconductor’s Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?
- Shopify’s Small Q3 Miss Triggered a Big Sell-Off: What’s Next?
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
Receive News & Ratings for Silexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
